The new funding, backed by private equity firm Thompson Street Capital Partners, enables Vector Laboratories to embark upon an acquisition strategy while accelerating the commercialization of innovative labeling and detection technologies for immunohistochemistry, immunofluorescence, glycobiology, and bioconjugation. Through the buyout, Vector Laboratories reasons, it has gained the flexibility of a well-funded startup combined with a market-tested product portfolio driving innovative research by academic, industrial, and clinical researchers worldwide . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge